Simon Bushell

Simon Bushell has a wide range of work experience in the field of chemical biology and therapeutics. Simon is currently working as the SVP of Molecular Discovery at Entact Bio since November 2022. Prior to that, they served as the Vice President and Head of Chemical Biology at Odyssey Therapeutics from September 2021 to November 2022. Before joining Odyssey Therapeutics, Simon held the position of Director of Chemical Biology at Merck from February 2019 to September 2021. Simon also worked at Novartis Institutes for BioMedical Research (NIBR) for a significant period of their career in various roles, including Sr. Investigator, Group Leader, and Investigator in Chemical Biology. Simon's expertise in chemical biology and their leadership experience make him a highly qualified professional in the industry.

Simon Bushell received their B.Sc. in Organic/Medicinal Chemistry from The University of Manchester in 1997. Simon then pursued a Ph.D. in Organic Chemistry at the same university from 1997 to 2000. Following this, they engaged in Postdoctoral Research at Clemson University from 2001 to 2002. Subsequently, they carried out further Postdoctoral Research in Organic Chemistry at Boston College from 2002 to 2004.